Table 1.
PASADENA; MAO-B inhibitor-treated vs. treatment-naïve patients, and PASADENA (all patients) vs. PPMI.
|
PASADENA MAO-B inhibitor-treated patients
(n = 115) |
PASADENA Treatment-naïve patients
(n = 201) |
SMD (CI) |
PASADENA
All patients (n = 316) |
PPMI
PD patients (n = 336) |
SMD (CI) | |
|---|---|---|---|---|---|---|
| Age, years mean (SD) | 58.2 (9.00) | 60.8 (9.00) | −0.290* (−0.520, −0.059) | 59.90 (9.10) | 61.30 (9.69) | 0.166 (0.012, 0.320) |
| Gender Male, n (%)† | 74 (64.3) | 139 (69.2) | −0.048 (−0.156, 0.060) | 213 (67.4) | 220 (65.5) | −0.019 (−0.092, 0.053) |
| Years of education, mean (SD) | 16.39 (5.20) | 15.22 (4.80) | 0.234 (0.006, 0.467) | 15.65 (4.99) | 15.53 (3.03) | −0.029 (−0.183, 0.125) |
| Time from diagnosis, months mean (SD) | 11.96 (6.10) | 9.06 (6.50) | 0.461* (0.225, 0.689) | 10.11 (6.50) | 6.44 (6.30) | −0.573* (−0.730, −0.417) |
| H&Y Stage II, n (%)† | 83 (72.2) | 155 (77.1) | −0.049 (−0.150, 0.051) | 238 (75.3) | 197 (59.0) | −0.167 (−0.238, −0.096) |
| RBDSQ (SD) | 3.51 (2.65) | 3.43 (2.75) | 0.031 (−0.199, 0.260) | 3.46 (2.71) | 4.14 (2.69) | 0.250 (0.095, 0.405) |
| DaT-SPECT contralateral putamen (SD) | 0.81 (0.24) | 0.78 (0.25) | −0.102 (−0.331, 0.128) | 0.80 (0.25) | 0.68 (0.27) | −0.445* (−0.601, −0.289) |
| DaT-SPECT ipsilateral putamen (SD) | 1.02 (0.30) | 1.09 (0.33) | −0.194 (−0.421, 0.038) | 1.06 (0.32) | 0.96 (0.39) | −0.285* (−0.439, −0.129) |
| MoCA (SD) | 28.27 (1.96) | 27.65 (2.04) | 0.309* (0.076, 0.539) | 27.87 (2.03) | 27.24 (2.29) | −0.291* (−0.446, −0.136) |
| SCOPA-AUT (SD) | 7.71 (4.82) | 8.25 (6.16) | −0.096 (−0.323, 0.136) | 8.05 (5.71) | 9.75 (6.23) | 0.284* (0.128, 0.439) |
| MDS-UPDRS sum of Parts I + II + III, mean (SD) | 30.21 (11.96) | 32.10 (13.20) | −0.150 (−0.378, 0.081) | 31.41 (12.78) | 32.63 (13.04) | 0.094 (−0.059, 0.248) |
| MDS-UPDRS Part I, mean (SD) | 4.49 (3.40) | 4.68 (4.06) | −0.051 (−0.279, 0.180) | 4.61 (3.83) | 5.60 (3.93) | 0.255* (0.100, 0.409) |
| MDS-UPDRS Part IA, mean (SD) | 0.96 (1.54) | 1.27 (1.67) | −0.195 (−0.422, 0.037) | 1.16 (1.62) | 1.27 (1.57) | 0.071 (−0.083, 0.224) |
| MDS-UPDRS Part IB, mean (SD) | 3.53 (2.50) | 3.14 (2.93) | 0.045 (−0.185, 0.273) | 3.45 (2.78) | 4.33 (3.10) | 0.297* (0.142, 0.451) |
| MDS-UPDRS Part II, mean (SD) | 5.19 (3.90) | 5.41 (4.13) | −0.055 (−0.284, 0.174) | 5.33 (4.04) | 6.12 (4.20) | 0.190 (0.036, 0.344) |
| MDS-UPDRS Part III, mean (SD) | 20.53 (8.81) | 22.01 (9.09) | −0.165 (−0.394, 0.065) | 21.47 (9.00) | 20.92 (8.88) | −0.062 (−0.216, 0.092) |
| MDS-UPDRS Part III Axial Symptoms, mean (SD)† | 0.77 (0.50) | 0.78 (0.57) | −0.004 (−0.233, 0.225) | 0.78 (0.54) | 0.68 (0.71) | −0.153 (−0.307, 0.001) |
| MDS-UPDRS Part III Bradykinesia, mean (SD)‡ | 9.91 (5.60) | 10.48 (5.49) | −0.102 (−0.331, 0.127) | 10.27 (5.53) | 10.60 (5.60) | 0.059 (−0.095, 0.212) |
| MDS-UPDRS Part III Rigidity, mean (SD)‡ | 3.90 (2.58) | 4.17 (2.83) | −0.103 (−0.331, 0.128) | 4.07 (2.74) | 3.86 (2.61) | −0.078 (−0.232, 0.075) |
| MDS-UPDRS Part III Resting Tremors, mean (SD)‡ | 2.71 (2.77) | 3.12 (2.74) | −0.147 (−0.377, 0.082) | 2.97 (2.75) | 2.58 (2.42) | −0.151 (−0.305, 0.003) |
Demographics and baseline disease characteristics compared using the SMD.
Indicates not balanced covariates (>0.25 SMD).
For binary variables the table shows the difference in proportions.
Part III subscores are defined as: Bradykinesia (sum of item 3.4, finger tapping; item 3.5, hand movements; item 3.6, pronation-supination movements of hands; item 3.7, toe tapping; item 3.8, leg agility; item 3.9, arising from chair; item 3.13, posture; and item 3.14, body bradykinesia); Rigidity (sum of item 3.3. [Neck, Upper Limbs and Lower Limbs]); Resting tremors (sum of item 3.17, rest tremor amplitude [Lip/Jaw, Upper Limbs and Lower Limbs] and Item 3.18, constancy of tremor); and axial symptoms (sum of item 3.10, gait; item 3.11, freezing of gait; and item 3.12, postural stability). CI, confidence interval; DaT-SPECT, dopamine transporter with single-photon emission computerized tomography; H&Y, Hoehn and Yahr; MAO-B, monoamine oxidase B; MDS-UPDRS, Movement Disorders Society—Unified Parkinson's Disease Rating Scale; MoCA, Montreal Cognitive Assessment; PD, Parkinson's disease; PPMI, Parkinson's Progression Markers Initiative; RBDSQ, Rapid Eye Movement Sleep Behavior Disorder Screening Questionnaire; SCOPA-AUT, Scales for Outcomes in Parkinson's Disease—Autonomic Dysfunction; SD, standard deviation; SMD, standardized mean difference.